Dr. Bertrand Tombal delivered a practical presentation titled “What Do You Need for Decision Making in mHSPC in 2026?”, ...
Edwin Posadas discusses RTOG 3506 (STEEL), a phase II trial adding enzalutamide to salvage radiation plus two years of androgen deprivation therapy in extremely high-risk post-pro ...
Dr. Fizazi began by revisiting the role of docetaxel in the mHSPC setting, emphasizing that treatment benefit varies ...
The 2026 European Association of Urology (EAU) annual meeting featured an advancements in upper tract urothelial carcinoma ...
Dr. Maluf emphasized that his discussion would focus on penile squamous cell carcinoma and genitourinary basket trials. At ...
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
The 2026 European Association of Urology (EAU) annual meeting featured a managing advanced disease in renal and rare cancer ...
This is the largest study exploring how we should treat people who present at A&E with blood in their urine. It’s a common problem affecting thousands of people around the world, and these patients ...
Germline testing can identify hereditary cancer, which leads to implications for family members, cascade testing for relatives, and starting surveillance and prevention measures: Genetic testing in ...
(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Himisha Beltran discussing how to read a ...
The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Martin Gleave discussing how to optimize tissue biopsy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results